RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma

Pediatric Blood and Cancer

Volumn 56, Issue 5, 2011, Pages 738-743

  Lee, Jun Ah ^a   Jung, Jun Soo ^a   Kim, Dong Ho ^a   Lim, Jung Sub ^a   Kim, Min Suk ^a   Kong, Chang Bae ^a   Song, Won Seok ^a   Cho, Wan Hyeong ^a   Jeon, Dae Geun ^a   Lee, Soo Yong ^a   Koh, Jae Soo ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Osteosarcoma; RANKL; Treatment outcome

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; MALE; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RANK LIGAND; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952131163     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22720     Document Type: Article

References (28)

1. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 2003; 9: 5442-5453.
2. Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli institute, Italy. Eur J Cancer 2005; 41: 2836-2845.
3. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003; 25: 845-853.
4. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004; 16: 120-125.
5. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian sarcoma groups. J Clin Oncol 2005; 23: 8845-8852.
6. Eselgrim M, Grunert H, Kuhne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the cooperative osteosarcoma study group (COSS) trials. Pediatr Blood Cancer 2006; 47: 42-50.
7. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92: 460-470.
8. Stejskal D, Bartek J, Pastorkova R, et al. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001; 145: 61-64.
9. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97: 887-892.
10. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
11. Chen G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-298.
12. Mikami S, Katsube K, Oya M, et al. Increased RANKL expression is related to tumor migration and metastasis of renal cell carcinomas. J Pathol 2009; 218: 530-539.
13. Rose AA, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010; 6: 55-74.
14. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008; 68: 92-104.
15. Akhtari M, Mansuri J, Newman KA, et al. Biology of breast cancer bone metastasis. Cancer Biol Ther 2008; 7: 3-9.
16. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14: 6690-6696.
17. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
18. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 2003; 163: 2021-2031.
19. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007; 67: 7308-7318.
20. Mori K, Berreur M, Blanchard F, et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive saos-2 human osteosarcoma cells. Oncol Rep 2007; 18: 1365-1371.
21. Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 2007; 211: 555-562.
22. Kim MS, Song WS, Cho WH, et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007; 459: 229-236.
23. Lee JA, Kim MS, Kim DH, et al. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 2008; 50: 195-200.
24. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006; 28: 261-269.
25. Avnet S, Longhi A, Salerno M, et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 2008; 33: 1231-1238.
26. Miyamoto N, Higuchi Y, Mori K, et al. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2002; 2: 25-38.
27. Pulsatelli L, Dolzani P, Silvestri T, et al. Soluble receptor activator of nuclear factor- kappaB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology 2004; 5: 119-127.
28. Kerschan-Schindl K, Wendlova J, Kudlacek S, et al. Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes 2008; 116: 491-495.